P048 | PLASMA GFAP LEVELS IN PATIENTS WITH MIGRAINE: LACK OF ASSOCIATION WITH CLINICAL PHENOTYPE AND DISEASE BURDEN
Confinia Cephalalgica · 03.11.2026 · 36 (s1)
DOI: 10.4081/cc.2026.16004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Growing evidence highlights the role of astrocytic activation and subsequent neuroinflammation in migraine pathophysiology, particularly in driving trigeminovascular sensitization. As a major intermediate filament protein of astrocytes Glial Fibrillary Acidic Protein (GFAP) directly reflects glial response and neuroinflammatory changes. Although GFAP is widely utilized to monitor neurodegenerative conditions, evidence regarding its correlation in migraine patients remains uncertain. This study aimed to evaluate plasma GFAP levels in migraine patients compared to healthy controls, and to investigate its association with specific clinical phenotypes, disease burden, and attack phases.
Methods
We conducted a cross-sectional observational study in patients with migraine and controls. Plasma GFAP concentrations were quantified using the fully automated Lumipulse® G1200 platform (Fujirebio, Ghent, Belgium). Clinical variables included monthly migraine days (MMD), pain intensity, migraine-related disability (MIDAS), headache impact (HIT-6), disease duration, migraine subtype (episodic or chronic), migraine with aura, medication-overuse headache (MOH), and ictal/interictal status. Group comparisons, Spearman correlation analyses, and multivariable linear regression analyses were performed.
Results
Seventy-one patients with migraine and 26 healthy controls were included. Plasma GFAP concentrations showed no statistically significant difference between cases and controls (18.40 [IQR 11.80–28.70] vs 18.10 [12.05–20.60] pg/mL; p=0.372); with no difference after adjustment for age. No significant differences were observed according to migraine chronicity, presence of aura, MOH, attack phase, sex or disease severity indices. A positive correlation was observed between plasma GFAP levels and age both in patients with migraine (ρ=0.470, p
Zitieren
APA
(2026). P048 | PLASMA GFAP LEVELS IN PATIENTS WITH MIGRAINE: LACK OF ASSOCIATION WITH CLINICAL PHENOTYPE AND DISEASE BURDEN. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.16004
Vancouver
P048 | PLASMA GFAP LEVELS IN PATIENTS WITH MIGRAINE: LACK OF ASSOCIATION WITH CLINICAL PHENOTYPE AND DISEASE BURDEN. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.16004
BibTeX
@article{euvimed2026,
title = {P048 | PLASMA GFAP LEVELS IN PATIENTS WITH MIGRAINE: LACK OF ASSOCIATION WITH CLINICAL PHENOTYPE AND DISEASE BURDEN},
journal = {Confinia Cephalalgica},
year = {2026},
volume = {36},
number = {s1},
doi = {10.4081/cc.2026.16004}
}
EUVIMED